Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Phase II Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

NCT07203053 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT07203053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07203053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Phase II Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2026
Completion date
October 31, 2029
Enrollment
48 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage lung small cell cancer